Scott Gottlieb

Scott Gottlieb, MD, is a Partner at New Enterprise Associates (NEA) in Washington, DC, where he leads investments within the firm's Healthcare team, focusing on biotechnology, biopharma, life sciences, and healthcare technology sectors. At NEA, he has been instrumental in supporting innovation-driven companies such as National Resilience, Comanche Biopharma, and Xaira Therapeutics, leveraging his expertise to identify and advance transformative healthcare solutions.

Dr. Gottlieb brings extensive healthcare policy and regulatory experience from his tenure as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), as well as prior roles as FDA Deputy Commissioner and Senior Adviser to the Centers for Medicare and Medicaid Services. In addition to his current NEA partnership, he serves as a Senior Fellow at the American Enterprise Institute and holds directorships with leading biotech and pharmaceutical companies, including Pfizer and Illumina.

An elected member of the National Academy of Medicine, Dr. Gottlieb holds an MD and completed his Internal Medicine residency at the Icahn School of Medicine at Mount Sinai, and earned his BA in Economics from Wesleyan University. His career is marked by a commitment to driving public health impact through investment and policy, advancing access to life-saving technologies, and shaping the landscape of healthcare entrepreneurship.